Phillip Jones, MD
Orthopaedic Surgery · Chico, CANPI 1922204494
Payments from drug & device makers
What this record shows
This record is dominated by education: $1,200 of the $1,692 with a category attached, or 70.9%. Steelhead Surgical Inc accounts for 70.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,224 and has fallen 75.7% since, to $298 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in CA, where the typical reported total is $2,444.
Across 12 payments — averaging $140.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Steelhead Surgical Inc$1K
- Stryker$173
- Arthrex$124
- Vericel Corporation$86
- Pacira Pharmaceuticals Incorporated$57
- Boston Scientific$28
- plus $24 from 1 others
What the payments were for
- Food & beverage$49229%
- Education$1,20071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Steelhead Surgical Inc | 1 | $1,200 |
| Stryker | 1 | $173 |
| Arthrex | 1 | $124 |
| Vericel Corporation | 3 | $86 |
| Pacira Pharmaceuticals Incorporated | 3 | $57 |
| Boston Scientific | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$173
How this compares
$1,692 in reported general payments places this provider in the 45th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 49 | $396 |
| Ondansetron OdtOndansetron | 33 | $376 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $357 |
| Cefadroxil | 34 | $326 |
| Oxycodone Hcl | 29 | $168 |
| Famotidine | 28 | $71 |
| Tramadol Hcl | 16 | $45 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Chico
- Bradford HackArcadia$18.3M
- Robert GorabOrange$13.6M
- Kelly VinceLos Angeles$9.6M
- Stephen HowellSacramento$9.4M
- Thomas CoonRed Bluff$9.2M
- Nirav AminPlacentia$5.6M
- Tom NorrisSan Francisco$5.3M
- Jay LiebermanLos Angeles$4.8M
- Peter NewtonSan Diego$4.2M
- Sigurd BervenSan Francisco$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.